Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements after treatment with the monoclonal antibody dupilumab. Chronic obstructive pulmonary disease patients with typ.
Phase 3 Trial: Dupilumab Reduces Type 2 Inflammation in COPD Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Velocity becomes one of largest site organisations in Europe in addition to being the largest in the U.S.Adds Oncology to therapeutic capability LONDON,.
Velocity accelerates European growth with acquisitions in Poland and Germany fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.